Neogenomics Unveils PanTracer Pro, A Strategic Move in Precision Oncology

Integrated Diagnostics to Accelerate Decisions

PanTracer Pro merges genomic analysis with immunohistochemistry in a single workflow. The system interrogates more than 500 cancer-relevant genes using both DNA and RNA sequencing, aiming to reduce diagnostic uncertainty and deliver robust biomarker data to oncologists within 8–10 days.

A standout feature is an built‑in reflex mechanism: if a tissue sample isn’t sufficient for a full analysis, the platform automatically pivots to a liquid biopsy, ensuring the diagnostic process can proceed without delaying treatment. CEO Tony Zook emphasizes that this blended approach is meant to speed up both the selection of effective therapies and the identification of relevant clinical trials.

Should investors sell immediately? Or is it worth buying Neogenomics?

Market Focus Ahead of the Results

The stock traded within a tight range today, between $11.28 and $11.33 per share. Market participants and researchers remain divided, with most analysts rating the stock as Buy or Hold. Price targets span from $11.00 to $17.00, and the consensus target sits roughly between $11.38 and $14.00.

Key Numbers and Upcoming Milestones for Neogenomics (NEO)

• Product launch: PanTracer Pro (February 12, 2026)
• Next event: Q4 2025 and full-year 2025 results on February 17, 2026 (pre-market)
• Expected Q4 revenue: approximately $188 million
• Analyst consensus: predominantly Buy/Hold
• Processing time per test: 8–10 days

Investors will focus on Tuesday, February 17, as Neogenomics discloses its fourth-quarter and full-year 2025 performance, with attention centered on the projected revenue of about $188 million and any potential improvements in operating margins relative to the prior year.